Compare Fastly Inc (FSLY) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Johnson & Johnson — how do they compare? Fastly Inc trades at $29.51 (market cap $4.03B), while Johnson & Johnson trades at $261.43 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 153.4× Fastly Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Fastly Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Johnson & Johnson for 129 Days on average.
| FSLY | JNJ | |
|---|---|---|
Market Cap | $4.03B | $618.09B |
Volume | 5,516,495 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $33.50 | $278.43 |
52-Week Low | $7.86 | $186.00 |
Typical Hold Time | 26 Days | 129 Days |
Enterprise Value | $4.09B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $29.3, up 15.9% on the day, with a neutral technical signal and bullish moving averages. The company reported three consecutive quarterly EPS beats, with Q3 2026 expected at $0.1186. Revenue growth is strong, reaching $624M in 2025, but net losses persist, though margins are improving. Recent news highlights AI-driven demand and insider selling by the CTO, creating mixed sentiment.
The outlook is cautiously optimistic, with revenue projected to hit $687M in 2026 and a path to profitability. Risks include sustained losses, competitive pressure, and high valuation multiples. Analyst consensus is mixed, with a $28.25 price target slightly below current levels, suggesting limited near-term upside amid growth execution risks.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
